208 related articles for article (PubMed ID: 30151080)
1. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
da Silva PN; da Conceição RA; do Couto Maia R; de Castro Barbosa ML
Medchemcomm; 2018 Aug; 9(8):1273-1281. PubMed ID: 30151080
[TBL] [Abstract][Full Text] [Related]
2. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
Maccari R; Ottanà R
J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
[TBL] [Abstract][Full Text] [Related]
3. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
Derosa G; Maffioli P
Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
[TBL] [Abstract][Full Text] [Related]
4. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
[TBL] [Abstract][Full Text] [Related]
5. A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors.
Chaurasia PP; Dholariya S; Kotadiya F; Bhavsar M
Cureus; 2021 Sep; 13(9):e18300. PubMed ID: 34722075
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
7. SGLT-2 Inhibitors: Focus on Dapagliflozin.
Siddiqui Z; Hadid S; Frishman WH
Cardiol Rev; 2024 Apr; ():. PubMed ID: 38666776
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors.
Lin YH
J Formos Med Assoc; 2018 Sep; 117(9):849-854. PubMed ID: 29477576
[TBL] [Abstract][Full Text] [Related]
9. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
10. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Imprialos KP; Sarafidis PA; Karagiannis AI
J Hypertens; 2015 Nov; 33(11):2185-97. PubMed ID: 26372321
[TBL] [Abstract][Full Text] [Related]
11. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions.
Pantelidis P; Kalliakmanis A; Mitas C; Sideris M; Grassos C; Pittaras A; Manolis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):86-93. PubMed ID: 29412123
[TBL] [Abstract][Full Text] [Related]
16. Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.
Chen HY; Chiu PY; Chang CJ; Tsai LL; Huang YL; Hsu JC
Clin Drug Investig; 2018 Dec; 38(12):1125-1133. PubMed ID: 30219950
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin review - safety and efficacy profile in patients with T2DM.
Jakher H; Chang TI; Tan M; Mahaffey KW
Diabetes Metab Syndr Obes; 2019; 12():209-215. PubMed ID: 30787627
[TBL] [Abstract][Full Text] [Related]
18. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.
Yanai H; Katsuyama H; Hamasaki H; Adachi H; Moriyama S; Yoshikawa R; Sako A
J Clin Med Res; 2016 Jan; 8(1):10-4. PubMed ID: 26668677
[TBL] [Abstract][Full Text] [Related]
20. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit.
Patel DK; Strong J
Diabetes Ther; 2019 Oct; 10(5):1771-1792. PubMed ID: 31456166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
